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There is limited data on factors associated with loss to follow-up (LTFU) of health 
care workers (HCWs) following occupational exposure to HIV, and most studies were 
conducted in an era when poorly tolerated antiretrovirals (ART) like zidovudine were 
used. 
Methods 
A retrospective cohort study was conducted of HCWs attending a referral hospital’s 
Occupational Health Clinic (OHC) in Cape Town, South Africa, for post-exposure 
prophylaxis (PEP) during a period when tenofovir (TDF) was available. Data was 
obtained from an existing database maintained by the OHC.  
Our primary outcome was to identify factors associated with LTFU at the 3-month 
visit, with secondary outcomes evaluating factors associated with LTFU at the 6-week 
and 6-months visits. We selected 7 variables a priori for our logistic regression model 
and ensured there were at least 10 outcome events per variable to minimize bias. 
Results 
Two hundred and ninety-three folders were evaluated for descriptive analysis. LTFU 
worsened with successive visits: 36% at 6 weeks, 60% at 3 months, and 72% at 6 
months. In multivariate analysis at the 3-month visit LTFU was associated with age 
(adjusted odds ratio (aOR), 0.6 per 10-year increase [95% CI, 0.5 to 0.9]), HCW 
category of doctor (aOR 2.7 [95% CI, 1.3 to 5.5]), and time from exposure to receiving 
PEP of more than 24 hours (aOR 5.9 [95% CI, 1.3 to 26.9]). 
Discussion 
Our finding that LTFU increases with successive visits is consistent with other studies. 
It is believed higher LTFU in younger HCWs may be related to the greater change and 
instability they experience in their younger years.  
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Doctors are more likely to be LTFU than other HCWs which could be related to 
concerns of confidentiality in performing HIV testing at their facility. Additionally, 
doctors may be making their own assessments of the risk of exposure. Lastly, doctors 
may be submitting their own blood samples for HIV testing instead of attending the 
OHC.  
One study showed longer time from exposure to receiving PEP was not associated 
with attendance of visits, but we showed this did influence LTFU at the 3-month visit. 
This could be explained by HCWs who present after 24 hours having a perceived 
lower benefit from PEP.  
Newer studies have shown that completion of PEP is based on the tolerability of ART 
and not on whether dual or triple therapy are used. This could explain why in our 
cohort there was no correlation between type of ART and LTFU.  
There is literature to support increased attendance of follow-up visits by contacting 
HCWs by telephone or mail. Furthermore, the WHO has recently advised the final 
follow-up visit to be at 3 months rather than 6 months. We suspect with fewer visits, 
there may be less LTFU.  
Conclusion 
We identified factors associated with LTFU of HCWs after occupational HIV exposure, 
which could be used to target interventions to improve follow-up. 
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Acronyms and abbreviations 
ART: antiretroviral therapy 
ATV/r: atazanavir/ritonavir 
CDC: Centre for Disease Control and Prevention 
GSH: Groote Schuur Hospital 
F/u: follow-up 
HIV: Human Immunodeficiency Virus 
HCW: health care worker 
LPV/r: lopinavir/ritonavir 
LTFU: lost to follow-up 
MeSH: medical subject headings 
ND: not documented 
PCS: prospective cohort study 
PEP: post-exposure prophylaxis 
RAL: raltegravir 
RCS: retrospective cohort study 
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SIV: Simian Immunodeficiency Virus 
TDF: tenofovir disoproxil fumarate 
USA: United States of America 
WHO: World Health Organization 
Glossary of terms 
Health care worker: all persons who work in a health care facility whom may be 
exposed to: infectious body fluids and tissue materials, or whom may come into 
contact with contaminated supplies, environmental surfaces or equipment. (1) 
Source: the patient from whom the health care worker was exposed to. 
Post-exposure prophylaxis: represents the use of antiretrovirals for the prevention 
of HIV infection in those exposed to a potential HIV source. (2) 
Mucocutaneous exposure: exposure of infectious material to non-intact skin, or 
mucus membranes. (3) 
Percutaneous exposure: is an exposure to infectious material with a needle, or 
sharp object. (3) 
Seroconversion: the period in time in which HIV-antibodies begin to develop to 
circulating HIV. (4) 
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Health care workers are at risk of developing infectious diseases from being exposed 
to occupational infectious material, with PEP as an important means of preventing 
HIV seroconversion among HCWs exposed to the virus. There are many other 
infectious diseases that HCWs are exposed to, but in this literature review we will 
concentrate on HIV only.  Anecdotally a large proportion of HCWs are LTFU at various 
visits. We hope to understand the factors that are associated with LTFU and the 
interventions that could decrease LTFU.  
Global burden 
HIV is a worldwide problem with 2.1 million new HIV infections reported in 2015, 
bringing the total number of people living with HIV to around 36 million. (5) South 
Africa currently has 7.03 million people living with HIV which equates to 12.7% of the 
population. (6) Furthermore, a study performed in a district hospital in Cape Town, 
South Africa, described 60% of their admissions were from HIV seropositive patients. 
(7) We can probably assume that a large proportion of these HIV infected individuals’
will at some point in their lives come into contact with HCWs. 
The World Health Organization (WHO) in 2002 estimated 3 million occupational HIV 
percutaneous exposures occur among 35 million HCWs annually, with 90% of 
exposures occurring in resource limited settings. Furthermore, it is estimated that 
worldwide 500 HCW HIV seroconversions occur on an annual basis. (8) These 
estimates are far smaller in developed countries. (1) 
Background to HIV post-exposure prophylaxis 
Immunological understanding of HIV is important in order to appreciate the 
importance of PEP. It is believed the administration of PEP will hinder HIV replication 
and thus prevent the development of systemic infection. The dendritic cells of the 
mucosa are the initial site for HIV-infection and in a primate model with Simian 
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Immunodeficiency Virus (SIV) infection the virus remains in the dendritic cells for 24 
hours before migrating to the regional lymph nodes for presentation to the T-
lymphocytes. (9, 10) After the regional lymph nodes are infected, dissemination into 
peripheral blood occurs within 5 days. (10) PEP is able to target the above steps, in 
order to prevent infection of the T-lymphocytes by HIV, and furthermore allow time 
for the immune system to develop cellular immunity against HIV. (11) 
Efficacy of PEP 
Animal models have shed light onto the importance of adherence to PEP. An animal 
model by Tsai et al, (12) demonstrated that sub-optimal duration of treatment and 
delay in initiating treatment are associated with PEP failure. This experiment, 
involving macaque monkeys inoculated with SIV, illustrated 100% efficacy if PEP 
was started within 24 hours; 50% efficacy if started after 48 hours, and 25% efficacy 
if started after 72 hours.  Furthermore, if PEP was given within 24 hours, but only 
continued for 3 days, all of the monkeys seroconverted; if 10 days of treatment was 
given, half seroconverted; while if a full 28-day regimen was prescribed, all 
macaques were protected. (11, 12) This is clinically relevant in educating HCWs of 
the importance of beginning PEP as soon as possible and to ensure adherence to 
PEP is maintained for the full 28 days. A more recent study, (13) involving rhesus 
monkeys infected with SIV, and ART begun at different time points of 3,7,10 and 14 
days, illustrated concerning findings that have implications for ART in PEP. 
Monkeys infected at day 3 had no detectable viraemia, but infection of lymphoid 
tissue was noted in all 4 monkeys after 3 days post inoculation with SIV. This 
illustrates that early seeding of the virus into lymphoid tissue can occur in the 
absence of viraemia. However, one needs to take into account these studies are 
based on animal models with SIV infection. Furthermore, studies of this nature will 
probably never be performed on humans due to ethical considerations.  
A study by Cardo et al, (14) illustrated zidovudine monotherapy was 81% effective in 
preventing occupational HIV seroconversion. However, one needs to take into 
account the study was a case-control retrospective study with small numbers of 
HCWs. (11) Furthermore, with the role out of more ART into the general population, 
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exposure to resistant virus is becoming a reality and the need to prescribe 
individualized ART regimens is essential. (15) Additionally, there are case reports of 
occupational HIV infection due to resistant HIV, even after ART was prescribed to 
HCWs. (16-18) 
History of PEP 
PEP has come a long way since the since the 1980’s. Initially, the PEP regimen of 
choice included monotherapy, zidovudine 100 mg four-hourly. However, the Centre 
for Disease Control and Prevention (CDC) only recommended the use of PEP in 1996. 
(1, 19) Currently, countries worldwide are using dual or triple ART for PEP, but the 
literature to support its use in occupational exposures is lacking. (20) However, 
prevention-of-mother-to-child-transmission studies have demonstrated superiority 
when using triple ART when compared with monotherapy ART. (21) 
Data from the United States of America (USA) between 1985 and 2013 showed 57 
cases of confirmed HIV seroconversion among HCWs and a further 138 potential 
cases. (22) The last reported case of HIV seroconversion in the USA was in 2008, in 
which a laboratory worker developed HIV after working with an HIV-live-culture. 
Before 2008, the last reported case was in 1999. The decrease in number of HIV 
seroconversion can be attributed to: increased uptake of universal standard 
precautions instituted in 1995, increased PEP utilization, and training to reduce 
exposure to infectious material. (1) 
Literature review 
Objectives of literature review: 
We aimed to identify factors associated with LTFU among HCWs who are exposed to 
HIV infection in the occupational setting. This literature review will look at the 
following factors: age, sex, HCW category, type of exposure, source patient HIV 
status, type of ART, and time from exposure to receiving PEP.  
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Literature search strategy: 
Articles only in English were considered. The following keywords and medical subject 
headings (MeSH) terms were utilized as part of the search strategy in: Pubmed, 
EBSCO Host (CINAHL, Academic Search Premier, African-wide Information, and 
Medline), Scopus, and Cochrane Library: 
• (HIV OR Human Immunodeficiency Virus) AND exposure
AND
• post-exposure prophylaxis OR postexposure prophylaxis OR post exposure
prophylaxis
AND
• Health personnel OR health care workers OR health care providers
AND
• Lost to follow up OR loss to follow up OR lost to follow-up OR loss to follow-up OR
adherence OR patient compliance OR attendance OR follow up
NOT
• pre-exposure
Table 1 illustrates articles identified from the various databases. Furthermore, figure 
1 illustrates the number of studies included and excluded from the literature review. 
Attendance to visits 
Attendance of HCWs to follow-up visits after occupational exposure to HIV has been 
highly variable, ranging from 0 to 98.9% in observational studies, table 2. (23-33) One 
study,(26) showed increased attendance to follow-up visits at the 6-month visit 
compared to the 3-month visit. This could be explained by the perception that HCWs 
may see the 6-month visit as more important compared with the 3-month, in ruling 
out HIV seroconversion. However, other studies have shown attendance of visits 
decreases with time. (24, 28, 29, 32)  
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We could only identify three studies that included more than 10 HCWs in their cohort 
that evaluated factors associated with attendance to follow-up, with inconsistency 
in the findings. (25, 32, 33)
17
 
Variables and relationship to loss to follow-up 
We hypothesized the following variables would be associated with LTFU: age, sex, 
type of HCW, type of exposure, source patient’s HIV status, type of ART, and time 
from exposure to receiving PEP.  
Age 
Studies have shown the majority of occupational exposures to infectious materials 
occur in younger HCWs who are in their twenties to thirties. (26, 29, 31, 33-35) This 
is probably related to a large proportion of HCWs being students or doctors, who are 
in their first year of practice, and are probably inexperienced and more likely to be 
involved in occupational exposures. (27, 29, 36, 37) Furthermore, it has been noted 
that younger patients are more likely to be LTFU, (38-40) which may be related to 
the greater change and instability they experience in their younger years. (41) Taking 
into account the above literature we postulated that young HCWs would be more 
likely to be LTFU.  
Sex 
There is little in the literature indicating which sex is more likely to be LTFU with 
occupational HIV exposure. Escudero et al (32) showed women were more likely to 
attend follow-up visits compared with men. Hence, we postulated men to be more 
likely to be LTFU.  
Category of health care worker 
Students and doctors are often involved in invasive medical procedures which places 
them at risk of being exposed to infectious material. (27, 29, 31, 37) One study, (26) 
looked at category of HCW and showed: 32% of doctors, and 28% of interns did not 
attend the 3-month follow-up visit, but that nurses were more likely to attend follow-
up visits. However, it is difficult to interpret the data, because the number of nurses 
in the study was small. This is in contrast to Gutierrez et al (25) who showed cleaning 
personnel were more likely to be LTFU. Again, it is difficult to interpret the data, 
because there were only 2 groups in the study: ‘Cleaning personnel’ and ‘Other 
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HCWs’. Two other studies, (32, 33) found type of HCW category did not influence 
attendance to follow-up. 
We postulated LTFU would be greater in doctors because of a number of factors. 
First, the ease with which doctors can submit their own blood samples for HIV testing 
instead of attending the OHC. One study, (42) showed a large proportion of HCWs 
obtained HIV testing outside of the facility where they worked. Reason cited for the 
above finding, was concerns surrounding confidentiality of testing for HIV at the 
facility. Second, doctors may be making their own assessment of the severity of the 
exposure and may deem it unnecessary to follow-up. (43) 
Type of exposure 
Not all exposures carry the same risk of acquiring HIV. Risk differs depending on the 
type of exposure: hollow-bore, solid sharp or mucocutaneous. Risk of HIV 
seroconversion after percutaneous exposure is estimated to be around 0.23% with 
no PEP. (44, 45) However, there are a number factors associated with a greater risk 
of acquiring HIV after percutaneous exposure: increased depth of injury, hollow bore 
needle, higher source patient’s HIV viral load, increased inoculum, a device 
previously inserted into the source patient’s artery or vein, and the absence of 
personal protection use such as gloves. (46, 47) Gloves have been shown to decrease 
blood volume transmission by 46-86%. (46) Risk due to mucocutaneous exposure is 
thought to be extremely low. (44) Other sources have evaluated the risk to be around 
0.03%. (11, 48) Percutaneous exposure to HIV has an incidence of around 70 to 97%, 
while mucocutaneous exposure is around 3 to 8%. (33, 35, 36, 49) One study, (26) 
showed follow-up increased in those with more severe exposures. However, 
Escudero et al, (32) showed this had no influence. We postulated that those exposed 
to more severe exposures would be less likely to be LTFU, due to increased possibility 
of HIV seroconversion.  
HIV source status 
Literature surrounding HIV source status and occupational exposure is conflicting, 
with one study showing source HIV status was not related to attendance of follow-
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up visits, (25) while another showed positive serological status was associated with 
improved follow-up. (32) One would expect HCWs exposed to an HIV seropositive 
source would be less likely to be LTFU compared to those where the source patient’s 
status is unknown, because of the real risk of contracting HIV from a seropositive 
source. Additionally, there is literature suggesting transmitted drug resistant HIV is 
increasing in South Africa. (50) It is unknown what the implications of exposure to 
drug resistant HIV would have on LTFU.  
Antiretroviral therapy regimen 
It has been shown that HIV seronegative HCWs suffer more side effects than HIV 
seropositive patients on the same regimen. (51) One study showed ART use for PEP 
was associated with a six times increased risk of side effects and eight times 
increased chance of discontinuing therapy when compared to HIV seropositive 
patients. (52) There are a number of studies which report that dual therapy is better 
tolerated than triple therapy. (53, 54) However, many of these studies include ART 
that are no longer used, due to their side effect profiles. Newer studies have shown 
that completion of PEP is based on the tolerability of ART and not on whether dual 
or triple therapy are used. (48, 55) Furthermore, one study, (56) found that 
raltegravir (RAL), used as the third agent in PEP, was better tolerated than 
lopinavir/ritonavir (LPV/r). In well-resourced areas RAL is the third drug of choice in 
PEP regimens due to its favourable tolerability profile. (57) To the best of our 
knowledge there are no studies looking at the effect of ART on occupational PEP with 
regard to LTFU. We aimed to evaluate the effect dual and triple therapy would have 
on LTFU.  
During the study period the Department of Health South African national guidelines 
for PEP recommended the use of TDF and emtricitabine for exposures presenting 
within 72 hours. The policy of adding a third antiretroviral (usually a boosted 
protease inhibitor) was changed during the study period: initially this was added only 
for high risk exposures, but subsequently this was added for all exposures. Figure 2 
shows the protocol followed by the OHC.  
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Time of exposure to receiving PEP 
PEP is rarely prescribed to those that present after 72 hours, because of poor efficacy. 
(12) However, most HCW present within the first few hours of exposure, allowing the
difficult decision of when to prescribe ART to those late presenters to be uncommon 
occurrence. (27, 42) One would expect, HCWs seeking medical intervention earlier 
are likely to have better insight into the benefits of PEP, resulting in improved follow-
up. However, a study by Escudero et al (32) showed time from exposure to receiving 
PEP did not influence attendance of visits.  
Underreporting 
Underreporting may affect the true incidence of the number of exposures and hence 
may affect the above aforementioned variables. Underreporting of exposures ranges 
from 35% to 78%. The causes of underreporting are due to the following: exposure 
being perceived as low risk for transmission of HIV, lack of knowledge of severity of 
exposure, fear of testing seropositive for HIV, concerns surrounding the 
confidentiality of HIV testing at the facility, HCWs being unaware of facilities available 
for reporting, lack of support from the hospital, unwillingness to take ART, 
inconvenience of follow-up and time constraints such as the procedure of reporting 
the exposure is time consuming. (29, 37, 42, 43, 58-62) 
Future areas of research 
Some HCWs may experience severe distress and fear of seroconverting after being 
exposed to infectious material, which may result in less LTFU, while others may feel 
a few days of ART will be adequate to prevent seroconversion, which may result in 
greater LTFU. These different circumstances necessitate adequate counselling. This 
may include counselling regarding exposure risk, coping mechanisms, donation of 
organs or blood, breastfeeding, use of condoms, and the risks and benefits of PEP. 
(48) Unfortunately with busy clinics, one may not spend adequate time on
counselling. This may be improved by developing protocols with checklists to confirm 
that all of the above factors are discussed with the HCW, as this could potentially 
affect LTFU.  
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There is currently little literature looking at the methods of decreasing LTFU in HCWs 
who present for PEP. However, Escudero et al (32) implemented a protocol in which 
the HCWs were contacted by telephone or mail. They showed attendance increased 
from 33.2% to 54%. Another study, (29) suggested increasing awareness through 
advertising of occupational health facilities and active tracing of those HCWs that are 
LTFU. One study, (60) suggested adherence to follow-up could be improved with 
fewer follow-up visits. The WHO has recently advised the final follow-up visit should 
be at 3 months instead of 6 months. (63) Furthermore, Gaines et al (64) suggested 
the last follow-up visit should be at 6 weeks if laboratory 4th generation HIV ELISA 
tests are used, and 8 weeks if 4th generation rapid HIV tests are used. A case report 
from 1990 describes a HCW who tested HIV seropositive after occupational exposure 
between eight to nine months. (65) However, 4th generation HIV ELISA tests were not 
available in the 1990’s, meaning our new generation tests are more likely to identify 
HIV earlier.  
We will advise making the final follow-up visit at 3 months. Furthermore, in the era 
of smart phones, one can set reminders to phones to attend visits. Furthermore, 
computerized text messages can be sent to HCWs reminding them of their upcoming 
visit. Studies will need to be performed to see if the above methods lead to decreased 
LTFU.  
Conclusion 
Post exposure prophylaxis treatment regimens have significantly improved with 
time, but concerns regarding management such as high rates of LTFU have been 
neglected and is an area that requires particular attention. There is little data looking 
at the factors surrounding LTFU, and the data identified have been inconsistent. It is 
hoped that this retrospective cohort study will shed light on these factors so as to 
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Table 1. Articles identified from various databases 
Database searched Results# Used* 
Pubmed 92 9 
Scopus 62 4 
EBSCO host 46 0 
Cochrane 12 0 
Total 212 13 
#Articles identified from the various databases. 




PRISMA flow diagram: Available from http://prisma-statement.org/ 
# Articles with less than 10 HCWs exposed to HIV seropositive source, references: 
(59, 66-71) 
Ω Articles with insufficient data looking at loss to follow-up, references: (60, 72, 73) 
*Studies included are illustrated in table 2.
Records identified through 
database searching 
(n =212) 
Additional records identified 
through other sources 
(n = 8)  
Records after duplicates removed 




(n = 121) 




Studies included in 
qualitative synthesis 
(n =11) * 
Full-text articles 




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
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Table 2. Illustrating various studies that looked at post-exposure prophylaxis across the globe, including: sample size, study design, and their respective 
follow-up periods 
Year  Site of study Reference Sample size (n) Study design 6-week f/u (%) 3-month f/u (%) 6-month f/u (%) Overall f/u (%)
2015 Ghana (33) 289 RCS 87 75 62 ND 
2015 Brazil# (32) 612 PCS ND 43.5 36.6 33.2 to 54* 
2011 Nigeria ❏ (31) 105 RCS ND ND ND 0 
2010 Nigeria ❏ (30) 48 RCS ND ND 83.7 ND 
2010 Malawi (29) 162 RCS ND 6.3 1.9 ND 
2009 Kenya (28) 91 RCS 32 ND 12 ND 
2009 India (27) 296 RCS ND ND ND 98.9 
2008 South Africa (26) 441 RCS ND 17 45 ND 
2005 Brazil◉ (25) 57 RCS ND ND ND 67 
1999 Thailand (24) 175 PCS ND 65 63 ND 
1998 France (23) 16 RCS ND ND ND 94 
Abbreviations: f/u: follow-up, ND: not documented, RC: retrospective cohort study, PC: prospective cohort study. 
#Included those exposed to HIV, Hepatitis B virus, and Hepatitis C virus.  
*Before and after the implementation of telephonic and mail reminders to health care workers of their upcoming visits.
❏Combination of post-exposure prophylaxis and non-occupational post-exposure prophylaxis cases.
◉Includes health care workers exposed to both HIV positive and unknown sources.
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Figure 2. Occupational Health Clinic Protocol for health care workers exposed to 
potentially infectious material$ 
$Adapted from “The management and treatment of hospital staff who have been 
accidentally exposed to blood or body fluids,” with permission from the Occupational 
Health Clinic.  
*Baseline bloods include: 4th generation Roche COBAS HIV-1/2 Combo automated
test with a confirmatory Siemens Integral 4th generation ELISA, Hepatitis B antibody
titre, Hepatitis C antibody, full blood count, creatinine, and alanine
aminotransferase.
ΩHCW: Health care worker.
#Source patients baseline bloods include: Hepatitis sAg, Hepatitis C antibody, HIV (if
not already known), and in cases where the source is known to be HIV positive a CD4
and viral load are taken.
Occupational exposure 
• 28 days of triple ART
• Follow-up at 6 weeks, 3 months and 6
months for HIV testing.
Source HIV seropositive 
Stop PEP 
Source HIV seronegative 
After hours: present to the emergency 
trauma unit. 
During office hours: presents to 
Occupational Health Clinic. 
Trauma unit 
• Triple ART (TDF/FTC/LPV/r) starter
pack given for 3 days.
• Baseline bloods of HCW taken.*
Occupational Health Clinic 
• Counselling.
• Baseline bloods of HCWΩ (if not
already taken in trauma unit)
• Source patients baseline bloods.#
• Check hepatitis B immunity and
vaccinate if necessary.
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Abstract 
Background 
There is limited data on factors associated with loss to follow-up (LTFU) of health 
care workers (HCWs) following occupational exposure to HIV, and most studies were 
conducted in an era when poorly tolerated antiretrovirals like zidovudine were used. 
Methods 
A retrospective cohort study was conducted of HCWs attending a referral hospital’s 
Occupational Health Clinic in Cape Town, South Africa for post-exposure prophylaxis 
(PEP) during a period when tenofovir was available. Our primary outcome was LTFU 
at the 3-month visit. We selected 7 variables a priori for our logistic regression model 
and ensured there were at least 10 outcome events per variable to minimize bias. 
Results 
Two hundred and ninety-three folders were evaluated for descriptive analysis. LTFU 
worsened with successive visits: 36% at 6 weeks, 60% at 3 months, and 72% at 6 
months. In multivariate analysis at the 3-month visit LTFU was associated with age 
(adjusted odds ratio (aOR), 0.6 per 10-year increase [95% CI, 0.5 to 0.9]), HCW 
category of doctor (aOR 2.7 [95% CI, 1.3 to 5.5]), and time from exposure to receiving 




We identified factors associated with LTFU of HCWs after occupational HIV exposure, 
which could be used to target interventions to improve follow-up.  
Keywords: loss to follow-up, post exposure prophylaxis, health care workers, HIV. 
Word count:  3811 
4Correspondence: gary.maartens@uct.ac.za  
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, 
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The World Health Organization (WHO) estimates 3 million occupational Human 
Immunodeficiency Virus (HIV) percutaneous exposures occur among 35 million 
healthcare workers (HCWs) annually, with 90% of exposures occurring in resource 
limited settings. [1] HCWs exposed to potentially infectious material from a source 
patient with HIV infection, or unknown HIV status, are offered post-exposure 
prophylaxis (PEP) if this is appropriate, and attend several follow-up visits for PEP 
toxicity monitoring and exclusion of HIV infection. Although HIV seroconversion 
following occupational exposure is uncommon, early diagnosis is critical as treatment 
of early HIV infection reduces the risk of HIV transmission and has direct benefits for 
the individual by reducing morbidity and mortality. [2, 3]  
Attendance of HCWs to follow-up visits after occupational exposure to HIV has been 
highly variable, ranging from 0 to 98.9% in observational studies. [4-13] A literature 
search yielded three studies that evaluated factors associated with attendance to 
follow-up. [6, 12, 13] Two studies found that the type of HCW category did not 
influence attendance to follow-up, [12, 13] but one study found that HCW category 
did influence attendance to follow-up. [6] One study identified being exposed to an 
HIV seropositive source increased attendance to follow-up, [13] but another found 
this had no effect. [6] One study [13] reported that type of exposure and time to 
reporting did not influence attendance to follow-up; and women had better 
attendance to follow-up than men. [13] Sample size calculations were not reported 
in any of these three studies. Furthermore, many of the PEP regimens used in these 
studies included poorly tolerated antiretroviral drugs. A recent systematic review 
reported that tenofovir disoproxil fumarate (TDF) based PEP was better tolerated 
with higher completion rates than zidovudine based PEP, which used to be the 
standard of care. [14] The WHO now recommends the use of TDF as part of the 
backbone for PEP regimens. [15]  
We aimed to evaluate factors associated with loss to follow-up (LTFU) following 
occupational exposure to HIV in a referral hospital in Cape Town, South Africa, where 
the HIV prevalence is 12.7%. [16] We conducted our study in a period when we 
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switched to TDF based PEP, and ensured we had sufficient power to determine 
variables associated with LTFU.  
Methods 
Study setting 
Data was collected from the Occupational Health Clinic (OHC) of Groote Schuur 
Hospital, a referral hospital in Cape Town, South Africa. HCWs who have significant 
occupational HIV exposure are started on PEP if they present within 72 hours of the 
exposure. During the study period the South African national guidelines for PEP 
recommended the use of TDF and emtricitabine for exposures presenting within 72 
hours. The policy of adding a 3rd antiretroviral (usually a boosted protease inhibitor) 
was changed during the study period: initially this was added only for high risk 
exposures, but subsequently this was added for all exposures. HCWs are counselled 
about the risks of HIV, the need to document HIV testing for possible 
compensation, and potential adverse drug reactions to PEP. HIV status of the HCW 
was determined at baseline using 4th generation Roche COBAS HIV-1/2 Combo 
automated test with a confirmatory Siemens Integral 4th generation ELISA. PEP was 
discontinued in HCWs who tested HIV seropositive at baseline. HIV testing was 
repeated at week 6 (when HCWs were informed that HIV tests may be false 
negative), and months 3 and 6 after the exposure. Confidentiality of HCWs is 
protected by keeping all files in the OHC and not in the general records 
department; only OHC clinic staff are able to access the files. 
Study design 
We conducted a retrospective cohort review to identify the factors associated with 
LTFU in HCWs following occupational HIV exposure. The OHC maintains an electronic 
database of all visits related to HCW occupational HIV exposures. We collected data 
from the database and additional data from folders between January 2013 and 
September 2015. Twenty-nine additional folders were obtained in 2012, but were 
unfortunately collected in alphabetical order and not according to time as completed 
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between 2013 and 2015. This being an oversight by the MMed candidate. However, 
we do not believe this oversight affected the results of the study.   
Outcomes 
The primary outcome was the proportion of HCWs LTFU at the 3-month visit, which 
is the key follow-up date to determine if HIV seroconversion has occurred, in keeping 
with the WHO guidelines. [15] Secondary outcomes were the proportion of HCWs 
LTFU at the 6-week and 6-month visits.  
Data collection 
Data collection at the OHC is collated from an “Occupational Health Clinic 
Percutaneous Inoculation Report” form. The data are collected each time the HCW 
presents for follow-up or when contacted by telephone. This form is completed by 
the occupational health worker on duty, who is either the nurse or doctor. Once 6 
months have lapsed since the last visit, the data collected are recorded in an 




HCWs were categorized into three groups: ‘Doctors’, ‘Students’ (e.g. medical, allied 
health, and nursing students) and ‘Allied Health Professionals’ (e.g. nursing, 
physiotherapists, occupational therapists, administrative clerks, pharmacists, and 
emergency medical services). HCWs were included if they were exposed to 
potentially infectious material from patients who are HIV-infected or HIV status 
unknown and attended the OHC. The following materials were deemed to be 
potentially infectious: pleural, pericardial, peritoneal, cerebrospinal, synovial fluid, 




Exclusion criteria were: HCW tested HIV seropositive at baseline; exposed to a HIV 
seronegative source; those who requested follow-up at a private doctor or who went 
back to their own training institutions, such as elective students; multiple exposures 
within the 6-month follow-up period; exposures deemed to be from non-infectious 
material. [17] 
Sample size estimation 
We selected seven variables a priori for inclusion into our model based on our review 
of the literature: age at exposure, sex, HCW category, type of exposure, source 
patient HIV status, dual or triple antiretroviral therapy (ART), and time from exposure 
to time of receiving PEP. Assuming 25% LTFU at 3 months, [12] we required a sample 
size of 280 to ensure a minimum of 10 outcome events per variable, which are 
needed to improve precision and minimize bias in logistic regression models [18].  
Statistical analysis 
All statistical analysis was performed using Stata (Version 13.1; Stata Corp, College 
Station, Texas, USA). Descriptive statistics were used to characterize the total 
sample, and results were expressed as median (interquartile range) for non-normally 
distributed continuous variables, and frequencies and percentages for categorical 
variables. 
We used separate multivariable logistic regression models for each time point to 
identify factors associated with LTFU at the 3-month, 6-week, and 6-month follow-
up visits. The full model approach was utilized using a priori selected variables in 
order to ensure decreased risk of selection bias and overfitting. [19] This approach 
allows multiple epidemiological variables to be assessed independently while 
controlling effects of other variables. [20] Univariate analysis was used to estimate 
crude odds ratios (ORs) and 95% confidence intervals (95% CIs), while multivariable 
logistic regression provided adjusted estimates for odds of LTFU at each time point. 
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Odds ratios were presented with 95% CIs and a level of p<0.05 was considered 
statically significant. 
Results 
Two hundred and sixty-four folders were obtained between January 2013 and 
September 2015, with an additional 29 folders collected according to alphabetical 
order in 2012. There was incomplete data on 12 HCWs who were included in the 
descriptive analysis but excluded from the univariate and multivariate analysis as 
shown in figure 3.  
The characteristics of the 293 patients from our cohort are shown in table 3.  The 
dual nucleotide/nucleoside reverse transcriptase inhibitors used in PEP were TDF 
(97%), zidovudine (2%), and stavudine (1%); all of which were combined with either 
lamivudine or emtricitabine. The third agent used in 210 HCWs who were given triple 
ART was: lopinavir/ritonavir (82%), atazanavir/ritonavir (13%), raltegravir (4%), and 
efavirenz (1%).  
LTFU at the various visits were: 36% at 6 weeks, 60% at 3 months, and 72% at 6 
months (table 3). The univariate and multivariate analysis of variables associated 
with LTFU at the 3-month visit are shown in table 4. In the multivariate analysis, 
significant risk factors associated with LTFU were: younger age, HCW category of 
doctor, and time from exposure to receiving PEP of more than 24 hours. The 
multivariate analysis of variables associated with LTFU at the 6-week and 6-month 
follow-up visits are shown in table 5. Variables associated with LTFU at the 6-week 
visit were: male sex and HCW category of doctor. Variables associated with LTFU at 
the 6-month visit were similar to the 3-month visit: younger age, HCW category of 
doctor, and time from exposure to receiving PEP of more than 24 hours. 
LTFU by category of HCW at the various visits is shown in figure 4, with doctors having 
the highest proportion LTFU. 
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Discussion 
We showed that LFTU of HCWs after occupational HIV exposure was high and 
increased with successive visits. Younger age, the HCW category doctor, and time 
from exposure to receiving PEP of more than 24 hours were associated with LTFU at 
the 3-month visit, which was our primary endpoint. Men were more likely to be LTFU 
at the 6-week visit than women. These findings could be used to target interventions 
designed to improve follow-up. 
Our finding that LTFU increases with successive visits is consistent with other studies. 
[9, 12, 13] We found that younger age was a significant risk factor for LTFU, which is 
in keeping with other studies. [21-23] The higher LTFU in younger HCWs may be 
related to the greater change and instability they experience in their younger years. 
[24] Men tended to be more likely to be LTFU in our study, which is similar to the
findings of Escurdero et al. [13] 
The majority (207 out of 281) of HCWs in our study were doctors and students. 
Doctors and students are often involved in invasive medical procedures, which places 
them at risk of being exposed to infectious material. [7, 9, 11, 25] Furthermore, 
students and doctors with less than a year’s experience, are prone to occupational 
exposure because of their inexperience. [7, 9, 26] We found that doctors are more 
likely to be LTFU than other HCW categories. This could be explained by the ease with 
which doctors can submit their own blood samples for HIV testing instead of 
attending the OHC. One study, [27] showed a large proportion of HCWs obtained HIV 
testing outside of the facility where they worked, which they suggested was due to 
concern surrounding the confidentiality of HIV testing at the facility. Furthermore, 
doctors may be making their own assessment of the severity of the exposure and 
may deem it unnecessary to follow-up. [28] In contrast to our findings of increased 
LTFU in doctors, Gutierrez et al [6] showed cleaning personnel were more likely to be 
LTFU. Two other studies found type of HCW category did not influence attendance 
to follow-up. [12, 13] 
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Longer time from exposure to receiving PEP at the 3-month visit was positively 
associated with LTFU. This could be explained by HCWs who present after 24 hours 
having a perceived lower benefit from PEP. However, type of exposure and source 
patient HIV status, which are associated with risk of HIV acquisition, were not 
associated with LTFU in our cohort. Escudero et al [13] also found that type of 
exposure was not related to attendance to follow-up. Findings from studies that 
assessed the effect of the source patient’s HIV status on LTFU are contradictory, with 
one study reporting no effect, [6] while another found positive serological status was 
associated with improved follow-up. [13]  
There are a number of studies which reported that dual ART regimens are better 
tolerated than triple regimens. [29, 30] However, many of these studies include ART 
that are no longer used due to toxicity. Newer studies have shown that completion 
of PEP is based on the tolerability of ART and not on whether dual or triple therapy 
are used. [31, 32] This could explain why in our cohort there was no correlation 
between type of ART used and LTFU.  
There were several limitations of our study. First, the retrospective cohort design is 
inherently prone to bias. However, the data was captured by OHC staff on a standard 
form and we had very little missing data. Second, although we found that time from 
exposure to receiving PEP was associated with LTFU, the 95% CIs were wide due to 
the small sample size of HCWs with delayed presentation. Third, we did not explore 
associations between years of HCW experience and exposure as we did not have this 
data. Other researchers have reported an association between years of experience 
and the incidence of occupational exposures. [7, 9, 25] Finally, Groote Schuur 
Hospital is a tertiary facility with referrals from other hospitals that fall under the 
University of Cape Town, so our findings may not be generalizable to other settings 
such as district hospitals. 
We have identified factors associated with LTFU, which could be used to target 
interventions to decrease LTFU.  In one study, [13] contacting HCWs by telephone or 
mail improved attendance to follow-up from 33% to 54%. Schmid et al [33] suggested 
attendance to follow-up could be improved with fewer follow-up visits. The WHO has 
45
 
recently advised the final follow-up visit should be at 3 months rather than 6 months. 
[15] Furthermore, it has been suggested that the last follow-up visit should be at 6
weeks if laboratory 4th generation HIV ELISA tests are utilized, and 8 weeks if 4th 
generation rapid HIV tests are utilized. [34] Lastly van der Maaten et al, [9] suggested 
increasing awareness of the availability of PEP through campaigns.  
Conclusion 
We have identified factors associated with LTFU of HCWs after occupational HIV 
exposure. Future research should identify measures to improve attendance to 
follow-up, which could be targeted at doctors, younger HCWs, and HCWs with 
delayed presentation.   
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Figure 3. Flow chart illustrating data set of health care workers chosen for analysis 
293 folders reviewed for 
descriptive analysis  
12 folders excluded due to missing data: 
• Health care worker (n=1)
• Type of exposure (n=7)
• Antiretroviral therapy (n=1)
• Time from exposure to time of
receiving PEP (n=2)
• Patient did not receive PEP because
presented after 72 hours following
exposure (n=1)
281 folders reviewed for 
univariate and 




Table 3: Baseline characteristics and follow-up of 293 health care workers with 
occupational exposure   
Variable Sample (n) 
Age, median (IQR) 28 (24-35) 
Sex 
Women 197 (67%) 
Men 96 (33%) 
Health care worker * 
  Allied Health Professional 85 (29%) 
  Doctor 100 (34%) 
  Student  107 (37%) 
Type of exposure# 
Hollow-bore 137 (48%) 
Mucocutaneous 86 (30%) 
Solid sharp 63 (22%) 
Source patient HIV status 
Positive 246 (84%) 
Unknown 47 (16%) 
Antiretroviral ⌘◉ 
Dual 81 (28%) 
Triple  210 (72%) 
Time from exposure to receiving PEP** 
<24 hours 268 (92%) 
24-48 hours 17 (6%) 
48-72hours 1 (0.3%) 
>72hours 4 (1.4%) 
Loss to follow-up❏ 
6 week 100 (36%) 
3 month 169 (60%) 
6 month 203 (72%) 
 Number with missing data: *n=1, #n=7, ⌘n=1, **n=2, ❏n=12 
◉One Health care worker did not receive PEP because presented too late
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Table 4: Variables associated with loss to follow-up at 3 months 
Variables Unadjusted OR (95% CI) P-value  Adjusted OR (95%CI) P-value
Age (per 10-year increase) 0.7 (0.5 to 0.9) 0.003 0.6 (0.5 to 0.9) 0.011 
Sex 
Women * 
Men 1.4 (0.8 to 2.4) 0.190 1.4 (0.8 to 2.5) 0.262 
Health care worker 
Allied Health Professional* 
Doctor 2.9 (1.6 to 5.4) 0.001 2.7 (1.3 to 5.5) 0.006 
Student  2.0 (1.1 to 3.6) 0.022 1.2 (0.6 to 2.6) 0.584 
Type of exposure 
Hollow-bore * 
Mucocutaneous 1.6 (0.9 to 2.9) 0.095 1.1 (0.6 to 2.2) 0.707 
Solid sharp 1.3 (0.7 to 2.4) 0.377 1.0 (0.5 to 1.9) 0.948 
Source patient HIV status 
Positive 0.9 (0.4 to 1.8) 0.742 0.5 (0.2 to 1.1) 0.074 
Unknown* 
Antiretroviral  
Dual 1.4 (0.8 to 2.3) 0.250 1.5 (0.8 to 2.8) 0.228 
Triple * 
Time from exposure to receiving PEP 
<24 hours * 




Table 5: Variables associated with loss to follow-up at 6 weeks and 6 months 
6-week 6-month
Variables Adjusted OR P-value Adjusted OR P-value
Age (per 10-year increase) 1.0 (0.7 to 1.3) 0.764 0.6 (0.5 to 0.9) 0.010 
Sex 
Women * 
Men 1.8 (1.1 to 3.2) 0.027 1.8 (0.9 to 3.4) 0.082 
Health care worker 
Allied Health Professional * 
Doctor 2.1 (1.1 to 4.4) 0.034 2.1 (1.0 to 4.5) 0.049 
Student 1.1 (0.5 to 2.5) 0.750 1.3 (0.6 to 2.9) 0.532 
Type of exposure 
Hollow-bore * 
Mucocutaneous 1.0 (0.5 to 1.9) 0.988 1.2 (0.6 to 2.5) 0.659 
Solid sharp 1.1 (0.5 to 2.1) 0.857 1.1 (0.5 to 2.4) 0.728 
Source patient HIV status 
Positive 1.0 (0.5 to 2.2) 0.952 0.7 (0.3 to 1.7) 0.489 
Unknown* 
Antiretroviral 
Dual 1.2 (0.6 to 2.3) 0.544 0.7 (0.4 to 1.4) 0.333 
Triple * 
Time from exposure to receiving PEP 
<24 hours * 




Figure 4. Percentage Loss to follow-up (LTFU) by number of visits of various health care worker categories (visits were 
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Anecdotally follow-up rates among health care workers after occupational exposure 
to Human Immunodeficiency Virus are poor. Identifying factors associated with poor 
follow-up could result in interventions to improve follow-up, such as enhanced 
counselling and reminders. The aim of this retrospective cohort study is to explore 
factors associated with loss to follow-up at the key 3-month visit using multivariate 
logistic regression. Secondary outcomes include loss to follow-up at the 6-week and 
6-month visits. Data will be extracted from an existing database maintained by the
Occupational Health Clinic of Groote Schuur Hospital, with missing data obtained 
from files maintained in the clinic. Data will be collected using Microsoft Excel. All 
patient identifiers will be kept completely confidential and only aggregate data will 
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According to the 2015 statistics of South Africa, the population was estimated to be 
54.96 million, of whom 6.19 million are living with Human Immunodeficiency Virus 
(HIV). This equates to 11.2% of South Africa’s population living with HIV, of whom a 
large proportion will at some time in their lives come into contact with Health care 
workers (HCWs). (1) 
The World Health Organization estimates 3 million HIV percutaneous exposures 
occur among 35 million HCWs annually, 90% of these exposures occur in resource 
limited settings and it is estimated that 500 occupational related HIV infections occur 
each year. (2) This is in stark contrast to developed countries where estimates are far 
smaller. (3) 
USA data, on occupational exposures, from 1985 to 2013 illustrated 58 confirmed 
cases and 150 possible cases of HIV seroconversion. However, since 1999 there has 
been only one confirmed case in 2008 of HIV seroconversion in a laboratory worker 
who sustained a percutaneous injury while working with live HIV culture. The 
decrease in number of cases can be attributed to the increased uptake of universal 
standard precautions instituted into the “standard precautions” in 1995; increased 
post-exposure prophylaxis (PEP) utilization, and training to reduce sharp exposures 
and other injuries. (3) 
PEP has come a long way from the 1980’s where single dose 100mg four hourly 
Zidovudine was used compared to the current gold standard of triple therapy either 
used once or twice daily. (4) There are no controlled data on the efficacy of PEP, and 
it is assumed that combination PEP will be superior to monotherapy, as is the case 
for prevention of mother-to-child transmission. A retrospective case control study by 
Cardo et al (5) showed an 81% reduction in occupational transmission of HIV when 
HCWs are given PEP with Zidovudine monotherapy. A recent article (6) showed there 
is little evidence to support the optimal number of drugs needed to prevent 
seroconversion among HCWs.  
Risk of HIV seroconversion after percutaneous exposure is 0.23% with no PEP. (7, 8) 
However, there are a number factors associated with a greater risk of acquiring HIV 
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after occupational exposure: increased depth of the injury, hollow bore needle, 
higher source patient’s HIV viral load, increased inoculum, device previously inserted 
into the source patient’s artery or vein, and absence of glove use. (9, 10) Gloves have 
been shown to decrease blood volume transmission by 46-86%. (9) Risk due to 
mucosal splash injury or non-intact skin is thought to be extremely low. (7) Other 
sources have evaluated the risk to be around 0.03%. (11) Percutaneous exposure to 
HIV is more common than mucosal splash exposure as shown in a number of studies. 
(12-14) To the best of our knowledge, there is currently no literature to indicate 
whether HCWs follow-up attendance after occupational HIV exposure is affected by 
the nature of the exposure. We believe HCWs may be less inclined to attend follow-
up after lower risk exposures.  
Unfortunately, the estimates of the number of exposures of HIV to HCWs is believed 
to be under-reported due to time constraints among HCWs. (15) A number of studies 
have shown that doctors are less likely to report injuries due to: work pressure, time 
constraints, and better understanding of risks involved in exposure compared to 
other HCWs. (15, 16)  
Adherence to PEP needs to be stressed among HCWs, as animal models have shown 
suboptimal duration of therapy and delay in starting PEP are associated with PEP 
failure. In a study by Tsai et al (17) protection of macaque monkeys against Simian 
Immunodeficiency Virus was optimal if treatment of PEP was started within 24 hours; 
if treatment was started after 48 hours it was 50% effective, and if started after 72 
hours it was only 25% effective. Furthermore, if PEP was given within 24 hours but 
only continued for 3 days, all of the monkeys seroconverted; if 10 days of treatment 
was given, half seroconverted; while if a full 28-day regimen was prescribed, all 
macaques were protected. (17, 18) The above information illustrates the need for 
optimal adherence and correct length of treatment to protect HCWs from HIV.  
HIV seronegative HCWs suffer more side effects than HIV seropositive patients on 
the same regimen. (19) One study (20) showed antiretroviral therapy (ART) use for 
PEP was associated with 6 times increased risk of side effects and 8 times higher 





are a number of studies which reported that 2-drug regimens were better tolerated 
than 3-drug regimens. (21, 22) However, many of these studies include 
antiretrovirals that are no longer used due to toxicity. Newer studies have shown that 
completion of PEP is based on the tolerability of ART prescribed and not on whether 
triple or dual therapy is used. (23)  
To the best of our knowledge, there is no data on lost to follow-up (LTFU) in 
occupational PEP with 2 versus 3-drug regimens. In the Occupational Health Clinic 
lopinavir/ritonavir or atazanavir/ritonavir were used as the third agent and not 
raltegravir, due to cost considerations. One study (24) found that raltegravir, used as 
the third agent in PEP, was better tolerated than lopinavir/ritonavir. In well-
resourced areas raltegravir is the third drug of choice in PEP regimens due to its 
favourable tolerability profile. (25)  
A study of adherence to ART among HIV infected patients in South Africa showed 
women were significantly more likely to adhere to treatment compared to men. (26) 
However, data with regard to ART adherence is conflicting; a systematic review by 
Nicastri et al,(27) found women were less likely to adhere to ART compared to men, 
but many of these studies were performed in first world settings. 
Two small studies in Nigeria, of people with both occupational and non-occupational 
exposure, reported 50% attendance within 24 hours of exposure in the first study, 
(28) and 100% attendance within 72 hours in the second study. (29) In both studies, 
men presented earlier than women for PEP. Failure to present within 24 hours of 
exposure was thought to be related to lack of awareness and following non-
occupational exposures. (28) While another study of occupational HIV exposure 
demonstrated 80% attendance within 24 hours of exposure. (30)  
There is currently a paucity in the literature of factors associated with LTFU after 
starting PEP. Studies that have evaluated this, have yielded highly variable results, 
with attendance ranging from 0% to 98.9%. (28-31) A study by Tetteh et al (30) 
described attendance of 87%, 75% and 62% at 6 weeks, 3 months and 6 months 
respectively. Unfortunately, the only factor they described with regards to 





statistically significant difference between the various categories of HCWs. A number 
of studies reporting attendance to follow-up did not asses the epidemiological 
factors surrounding attendance to follow-up. (28, 29, 31)  
As illustrated above there is little literature on factors surrounding LTFU among 
HCWs. It is hoped that this Master of medicine (MMed) dissertation will identify and 
explore these factors.  If HCWs are identified at high risk for LTFU, then additional 
counselling and other measures (e.g. text messaging) could be implemented to 
improve follow-up. 
HYPOTHESIS, STUDY AIMS AND OBJECTIVES  
HYPOTHESES 
We hypothesize that identifiable variables related to the exposed HCW; the nature 
of the occupational exposure, and/or the type of PEP will be associated with LTFU. 
Furthermore, we hypothesize attendance will decrease with time.  
STUDY AIMS  
To explore factors related to LTFU after occupational HIV exposure at the 
Occupational Health Clinic of Groote Schuur Hospital primarily at 3 months, and 
secondarily at 6 weeks and 6 months. 
STUDY OBJECTIVES 
1. To describe the epidemiology of HIV exposures among HCWs who received 
PEP at the Occupational Health Clinic. 
2. To describe the proportion of HCWs attending follow-up visits at 6 weeks, 3 
and 6 months.  
3. To determine predictors of LTFU visits at 6 weeks, 3 and 6 months using 








METHODS   
STUDY DESIGN 
Retrospective cohort study. 
STUDY SETTING 
Groote Schuur Hospital Occupational Health Clinic.  
STUDY POPULATION 
INCLUSION CRITERIA 
• HCWs (including healthcare professional students) with a significant 
occupational exposure to potentially infectious material from patients’ who 
are HIV-infected or HIV status unknown, and who attended the Groote Schuur 
Hospital Occupational Health Clinic. The following are deemed to be 
infectious: pleural, pericardial, peritoneal, cerebrospinal, synovial fluid,  
amniotic fluid and blood. (32)  
EXCLUSION CRITERIA 
• HCWs exposed to a HIV negative source.  
• Exposure deemed to be from non-infectious material. The following are not 
considered infectious unless visibly stained with blood: faeces, sputum, nasal 
secretions, urine, sweat, tears and vomitus. (32) 
• HCWs who tested HIV seropositive or “Unknown” HIV result at time of 
exposure.  
• Non-occupational exposures.  
• HCWs who requested follow-up at a private doctor or who went back to their 
own training institutions, such as in elective students. 
• HCWs with multiple injuries with overlapping time points, as these HCWs may 
be less likely to be LTFU due to multiple injuries, and increased risk of HIV 







Data will be collected using the Microsoft Excel spreadsheet in use by the 
Occupational Health Clinic. The study period will look retrospectively from 
September 2015 until 240 HCWs fulfilling the inclusion criteria are evaluated (see 
sample size below).  
HCWs are seen at first presentation and then followed up after 6 weeks, 3 months 
and 6 months. The window for each of the three follow-up visits are: 
• ≥4 to ≤10 weeks for the 6-week follow-up visit. 
• >10 to ≤20 weeks for the 3-month follow-up visit. 




Since currently used HIV antibody tests detect HIV infection within 3 months of 
exposure, even allowing for a possible delay in seroconversion due to PEP, we 
will describe the proportion of HCWs LTFU at the 3-month visit. (33, 34) 
SECONDARY OUTCOME  
Our secondary outcome will be the proportion of HCWs LTFU at the 6 week and 
6-month visits.  
VARIABLES FOR LOGISTIC REGRESSION 
The full model approach will be utilized; as a priori selected variables will be included 
in the multivariable analysis. Predictors that have been assessed not to contribute to 
the outcomes in the multivariable analysis have be withdrawn. This is to ensure 
decreased risk of selection bias and overfitting. (35)  
A multivariable logistic regression model will be developed with 6 variables identified 
below for both primary and the secondary outcomes. (36) We have chosen a 
multivariable logistic regression model because this will allow us to look at multiple 





effects of others. This will allow us to determine our outcomes of attendance at the 
various appointments and the independent epidemiological variables related to it. 
(37)  
The following variables have been chosen: 
 
1. Sex: we postulate that women will have less LTFU compared to men, in 
keeping with the better ART adherence among women in Southern Africa. 
(26) 
2. Age: Younger HCWs are more likely to be LTFU, which may be related to 
more chaotic lifestyles younger individuals experience. (38)  
3. HCW category: doctors are expected to have the highest proportion of 
LTFU. (15, 16) The following HCW categories will be used for analyses: 
▪ Doctors: interns, medical officers, registrars and consultants. 
▪ Students: medical, nursing, allied health and pharmaceutical.  
▪ Allied health: physiotherapist, radiographer, social worker, 
dietician, speech therapist, audiologist, occupational 
therapist, pharmacist, enrolled nurse, enrolled nurse assistant 
and registered nurse. 
▪ Other: recipients in support services, engineering, sterilization, 
clerical, emergency services, forensic pathology laboratory 
services and undefined where a category could not be 
identified.  
4. Type of exposure: HCWs with higher risk exposures, as defined in the 
background section, are less likely to be LTFU. 
5. Length of time from exposure to receiving PEP:  HCWs seeking medical 
intervention earlier are likely to have more insight into the benefits of 
PEP, which could result in less LTFU.  
6. PEP regimen: HCWs placed on dual therapy are less likely to be LTFU, 
because they are less likely to experience side effects as compared to 







The study by Tetteh et al (30) described follow up attendance of 75% at 3 months. 
Our primary end point is LTFU at 3-months.  
According to a logistic regression analysis model by Peduzzi et al: (36) 10 events per 
variable are needed to improve precision. As we have identified 6 variables 
potentially associated with LTFU, we need 60 outcomes. Assuming 25% LTFU at 3 
months, we need a sample size of 240. However, if during the study, attendance of 
the 3-month follow-up is seen to be more than 75%, we will adjust our sample size 
accordingly. If follow-up is noted to be lower than 75% at 3 months, we’ll keep the 
sample size unchanged as this will increase our power. 
DATA COLLECTION 
Data will be collected from the Occupational Health Clinic in Groote Schuur Hospital. 
Data has already been collated on an “Occupational Health Clinic Percutaneous 
Inoculation Report” form. The data is collected each time the HCW presents for 
follow-up or when telephonically contacted. The form is completed by the 
occupational health worker on duty, which is either the sister in charge or doctor on 
duty.  6 months after the last visit, namely the 6-month appointment, the data 
collated from the folders are placed in an electronic database and stored in the clinic. 
Data will be extracted from the “Occupational Health Clinic Percutaneous Inoculation 
Report” form and electronic database. All forms will be kept confidential and will not 
be removed from the clinic. If data is missing from forms, files will be requested from 
records for completion of the study spreadsheet. All information surrounding 
recipients and source patients shall be kept confidential. This will be ensured by a 
password protected laptop, and back-ups on an encrypted USB flash drive and 
password protected Dropbox application. The researchers will keep all passwords 
safe and shall not be shared with any other HCWs.  
CONFIDENTIALITY  
A unique identifying number will be issued to each HCWs in-place of their name and 





number correlating to the name and hospital number of the HCW. The spreadsheet 
with the unique identifier number and personal information will be deleted once all 
data has been collected.  
QUALITY ASSURANCE  
Quality assurance will be ensured by using the Microsoft Excel spreadsheet from the 
Occupational Health Clinic electronic database. There will be only one person 
involved in data collection which will be the MMed candidate and therefore no 
training is needed for extraction of data. Quality control will be ensured by seeking 
help from a statistician with regard to using software to prevent double entries from 
occurring in the electronic database as well as assimilation of data into flow 
diagrams, tables and charts. (39) 
DATA ANALYSIS  
Data will be captured using Microsoft Excel.  
Adjusted odds ratios will be presented together with 95% confidence intervals in 
order to determine the precision of estimates.  A level of p<0.05 will be considered 
statistically significant where appropriate.   
Descriptive statistics will be used to characterize the total sample and compare 
results between those who attended the follow-up visits versus non-attendance.  
  
Continuous variables will be tested for normality using histograms and exploratory 
analysis, and expressed using means (standard deviations) or medians (interquartile 
ranges) depending on their distributions, while categorical variables will be 
expressed as frequencies and percentages. 
  
Group comparisons of continuous variables will be analyzed using either parametric 
tests (two-sample t-test) or non-parametric tests (Mann-Whitney U test) depending 
on the distribution.  Chi-square test or Fisher’s Exact tests will be used to test for 
associations between categorical variables.   Depending on the nature of two 





the direction and strength of the relationship. 
  
All statistical analysis will be performed using Stata (Version 13.1; Stata Corp, College 
Station, Texas, USA).  
ETHICS  
• Clearance from the Human Research Ethics Committee of the University of 
Cape Town will be obtained for permission to extract data from the electronic 
database, forms in the Occupational Health Clinic as well as access files from 
records if not all information is available from the forms and electronic 
database.  
• As stated in “Methods” all information will be kept safe through password 
protected laptop, encrypted USB flash drive and password protected Dropbox 
application. HCW data will be deleted once all data has been collected, so as 
to ensure the data cannot be traced back to the HCW.  
• The benefits of the study will include understanding of the epidemiological 
factors surrounding LTFU of PEP and to explore possible methods to ensure 
better follow-up.  
• Neither Prof Maartens or myself have any conflicts of interest or ties with the 
Occupational Health Clinic. 
TIMING  
• The study will run retrospectively from September of 2015. 
• Protocol will be submitted to the Postgraduate Committee in April 2016. 
• Ethics submission will be in May 2016.  
• Data analysis will be completed in July 2016.  
• Manuscript preparation and completion will be accomplished by 30th of 
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The principal investigator and researcher will meet on a regular basis to discuss the 










• Any unforeseen costs incurred during the study will be funded by the MMed 
candidate.  
REPORTING OF RESULTS  
Results will be tabulated, graphed and designed in flow diagrams. Access to the 
information will be firstly distributed to the relevant members assisting in the study 
as well as Occupational Health Clinic. Finally, all data will be shared with the Health 
Science Faculty of the University of Cape Town and will be published in a relevant 
journal. 
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after occupational HIV exposure in Cape Town, 
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Abstract 
Background: There is limited data on factors associated with loss to follow-up (LTFU) of health care workers (HCWs) 
following occupational exposure to HIV, and most studies were conducted in an era when poorly tolerated antiretro-
virals like zidovudine were used.
Methods: A retrospective cohort study was conducted of HCWs attending a referral hospital’s Occupational Health 
Clinic in Cape Town, South Africa for post-exposure prophylaxis (PEP) during a period when tenofovir was available. 
Our primary outcome was LTFU at the 3-month visit. We selected seven variables a priori for our logistic regression 
model and ensured there were at least 10 outcome events per variable to minimize bias.
Results: Two hundred and ninety-three folders were evaluated for descriptive analysis. LTFU worsened with succes-
sive visits: 36% at 6 weeks, 60% at 3 months, and 72% at 6 months. In multivariate analysis at the 3-month visit LTFU 
was associated with age (adjusted odds ratio (aOR), 0.6 per 10-year increase [95% CI, 0.5–0.9]), HCW category of doctor 
(aOR 2.7 [95% CI, 1.3–5.5]), and time from exposure to receiving PEP of more than 24 h (aOR 5.9 [95% CI, 1.3–26.9]).
Conclusion: We identified factors associated with LTFU of HCWs after occupational HIV exposure, which could be 
used to target interventions to improve follow-up.
Keywords: Loss to follow-up, Post exposure prophylaxis, Health care workers, HIV
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Background
The World Health Organization (WHO) estimates 3 
million occupational human immunodeficiency virus 
(HIV) percutaneous exposures occur among 35 million 
healthcare workers (HCWs) annually, with 90% of expo-
sures occurring in resource limited settings [1]. HCWs 
exposed to potentially infectious material from a source 
patient with HIV infection, or unknown HIV status, are 
offered post-exposure prophylaxis (PEP) if this is appro-
priate, and attend several follow-up visits for PEP toxic-
ity monitoring and exclusion of HIV infection. Although 
HIV seroconversion following occupational exposure 
is uncommon, early diagnosis is critical as treatment of 
early HIV infection reduces the risk of HIV transmission 
and has direct benefits for the individual by reducing 
morbidity and mortality [2, 3].
Attendance of HCWs to follow-up visits after occupa-
tional exposure to HIV has been highly variable, rang-
ing from 0 to 98.9% in observational studies [4–13]. A 
literature search yielded three studies that evaluated fac-
tors associated with attendance to follow-up [6, 12, 13]. 
Two studies found that the type of HCW category did 
not influence attendance to follow-up, [12, 13] but one 
study found that HCW category did influence attend-
ance to follow-up [6]. One study identified being exposed 
to an HIV seropositive source increased attendance to 
follow-up, [13] but another found this had no effect [6]. 
One study [13] reported that type of exposure and time 
to reporting did not influence attendance to follow-up; 
and women had better attendance to follow-up than 
men [13]. Sample size calculations were not reported in 
any of these three studies. Furthermore, many of the PEP 
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regimens used in these studies included poorly tolerated 
antiretroviral drugs. A recent systematic review reported 
that tenofovir disoproxil fumarate (TDF) based PEP was 
better tolerated with higher completion rates than zido-
vudine based PEP, which used to be the standard of care 
[14]. The WHO now recommends the use of TDF as part 
of the backbone for PEP regimens [15].
We aimed to evaluate factors associated with loss to 
follow-up (LTFU) following occupational exposure to 
HIV in a referral hospital in Cape Town, South Africa, 
where the HIV prevalence is 12.7% [16]. We conducted 
our study in a period when we switched to TDF based 
PEP, and ensured we had sufficient power to determine 
variables associated with LTFU.
Methods
Study setting
Data was collected from the Occupational Health Clinic 
(OHC) of Groote Schuur Hospital, a referral hospital in 
Cape Town, South Africa. HCWs who have significant 
occupational HIV exposure are started on PEP if they 
present within 72  h of the exposure. During the study 
period the South African national guidelines for PEP rec-
ommended the use of TDF and emtricitabine for expo-
sures presenting within 72 h. The policy of adding a 3rd 
antiretroviral (usually a boosted protease inhibitor) was 
changed during the study period: initially this was added 
only for high risk exposures, but subsequently this was 
added for all exposures. HCWs are counselled about the 
risks of HIV, the need to document HIV testing for pos-
sible compensation, and potential adverse drug reactions 
to PEP. HIV status of the HCW was determined at base-
line using 4th generation Roche COBAS HIV-1/2 Combo 
automated test with a confirmatory Siemens Integral 
4th generation ELISA. PEP was discontinued in HCWs 
who tested HIV seropositive at baseline. HIV testing was 
repeated at week 6 (when HCWs were informed that HIV 
tests may be false negative), and months 3 and 6 after the 
exposure. Confidentiality of HCWs is protected by keep-
ing all files in the OHC and not in the general records 
department; only OHC clinic staff are able to access the 
files.
Study design
We conducted a retrospective cohort review to identify 
the factors associated with LTFU in HCWs following 
occupational HIV exposure. The OHC maintains an elec-
tronic database of all visits related to HCW occupational 
HIV exposures. We collected data from the database and 
additional data from folders between January 2013 and 
September 2015, with 29 additional folders obtained in 
2012.
Outcomes
The primary outcome was the proportion of HCWs 
LTFU at the 3-month visit, which is the key follow-up 
date to determine if HIV seroconversion has occurred, in 
keeping with the WHO guidelines [15]. Secondary out-
comes were the proportion of HCWs LTFU at the 6-week 
and 6-month visits.
Data collection
Data collection at the OHC is collated from an “Occupa-
tional Health Clinic Percutaneous Inoculation Report” 
form. The data are collected each time the HCW presents 
for follow-up or when contacted by telephone. This form 
is completed by the occupational health worker on duty, 
who is either the nurse or doctor. Once 6  months have 
lapsed since the last visit, the data collected are recorded 
in an electronic database using Microsoft Excel and 
HCW folders are then archived in the clinic.
Study population
Inclusion criteria
HCWs were categorized into three groups: ‘Doctors’, 
‘Students’ and ‘Allied Health Professionals’ (e.g. nursing, 
physiotherapists, occupational therapists, administrative 
clerks, pharmacists, and emergency medical services). 
HCWs were included if they were exposed to potentially 
infectious material from patients who are HIV-infected 
or HIV status unknown and attended the OHC. The fol-
lowing materials were deemed to be potentially infec-
tious: pleural, pericardial, peritoneal, cerebrospinal, 
synovial fluid, amniotic fluid, and blood [17].
Exclusion criteria
Exclusion criteria were: HCW tested HIV seropositive 
at baseline; exposed to a HIV seronegative source; those 
who requested follow-up at a private doctor or who went 
back to their own training institutions, such as elective 
students; multiple exposures within the 6-month follow-
up period; exposures deemed to be from non-infectious 
material [17].
Sample size estimation
We selected seven variables a priori for inclusion into 
our model based on our review of the literature: age at 
exposure, sex, HCW category, type of exposure, source 
patient HIV status, dual or triple antiretroviral therapy 
(ART), and time from exposure to time of receiving PEP. 
Assuming 25% LTFU at 3  months, [12] we required a 
sample size of 280 to ensure a minimum of 10 outcome 
events per variable, which are needed to improve pre-
cision and minimize bias in logistic regression models 
[18].
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Statistical analysis
All statistical analysis was performed using Stata (Ver-
sion 13.1; Stata Corp, College Station, Texas, USA). 
Descriptive statistics were used to characterize the total 
sample, and results were expressed as median (interquar-
tile range) for non-normally distributed continuous vari-
ables, and frequencies and percentages for categorical 
variables.
We used separate multivariable logistic regression 
models for each time point to identify factors associated 
with LTFU at the 3-month, 6-week, and 6-month follow-
up visits. The full model approach was utilized using a 
priori selected variables in order to ensure decreased 
risk of selection bias and overfitting [19]. This approach 
allows multiple epidemiological variables to be assessed 
independently while controlling effects of other variables 
[20]. Univariate analysis was used to estimate crude odds 
ratios (ORs) and 95% confidence intervals (95% CIs), 
while multivariable logistic regression provided adjusted 
estimates for odds of LTFU at each time point. Odds 
ratios were presented with 95% CIs and a level of P < 0.05 
was considered statically significant.
Results
Two hundred and sixty-four folders were obtained 
between January 2013 and September 2015, with an addi-
tional 29 folders collected according to alphabetical order 
in 2012. There was incomplete data on 12 HCWs who were 
included in the descriptive analysis but excluded from the 
univariate and multivariate analysis as shown in Fig. 1.
The characteristics of the 293 patients from our cohort 
are shown in Table  1. The dual nucleotide/nucleoside 
reverse transcriptase inhibitors used in PEP were TDF 
(97%), zidovudine (2%), and stavudine (1%); all of which 
were combined with either lamivudine or emtricitabine. 
The third agent used in 210 HCWs who were given triple 
ART was lopinavir/ritonavir (82%), atazanavir/ritonavir 
(13%), raltegravir (4%), and efavirenz (1%).
LTFU at the various visits were: 36% at 6  weeks, 60% 
at 3 months, and 72% at 6 months (Table 1). The univari-
ate and multivariate analysis of variables associated with 
LTFU at the 3-month visit are shown in Table 2. In the 
multivariate analysis, significant risk factors associated 
with LTFU were: younger age, HCW category of doc-
tor, and time from exposure to receiving PEP of more 
than 24  h. The multivariate analysis of variables associ-
ated with LTFU at the 6-week and 6-month follow-up 
visits are shown in Table  3. Variables associated with 
LTFU at the 6-week visit were: male sex and HCW cat-
egory of doctor. Variables associated with LTFU at the 
6-month visit were similar to the 3-month visit: younger 
age, HCW category of doctor, and time from exposure to 
receiving PEP of more than 24 h.
LTFU by category of HCW at the various visits is 
shown in Fig. 2, with doctors having the highest propor-
tion LTFU.
293 folders reviewed for 
descriptive analysis 
12 folders excluded due to missing data:
• Health care worker (n=1)
• Type of exposure (n=7)
• Antiretroviral therapy (n=1)
• Time from exposure to time of receiving PEP 
(n=2)
• Patient did not receive PEP because presented 
after 72 hours following exposure (n=1)281 folders reviewed for 
univariate and 
multivariate analysis 
Fig. 1 Flow chart illustrating data set of health care workers chosen 
for analysis
Table 1 Baseline characteristics and  follow-up of  293 
health care workers with occupational exposure
Number with missing data: a n = 1, b n = 7, c n = 1, d n = 2, e n = 12
f  One health care worker did not receive PEP because presented too late
Variable Sample (n)
Age, median (IQR) 28 (24–35)
Sex
 Women 197 (67%)
 Men 96 (33%)
Health care  workera
 Allied health professional 85 (29%)
 Doctor 100 (34%)
 Student 107 (37%)
Type of  exposureb
 Hollow-bore 137 (48%)
 Mucocutaneous 86 (30%)
 Solid sharp 63 (22%)
Source patient HIV status
 Positive 246 (84%)
 Unknown 47 (16%)
Antiretroviralc,f
 Dual 81 (28%)
 Triple 210 (72%)
Time from exposure to receiving  PEPd (h)
 <24 268 (92%)
 24–48 17 (6%)
 48–72 1 (0.3%)
 >72 4 (1.4%)
Loss to follow-upe
 6 weeks 100 (36%)
 3 months 169 (60%)
 6 months 203 (72%)
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Discussion
We showed that LFTU of HCWs after occupational HIV 
exposure was high and increased with successive visits. 
Younger age, the HCW category doctor, and time from 
exposure to receiving PEP of more than 24 h were associ-
ated with LTFU at the 3-month visit, which was our pri-
mary endpoint. Men were more likely to be LTFU at the 
6-week visit than women. These findings could be used to
target interventions designed to improve follow-up.
Our finding that LTFU increases with successive visits 
is consistent with other studies [9, 12, 13]. We found that 
younger age was a significant risk factor for LTFU, which 
is in keeping with other studies [21–23]. The higher LTFU 
in younger HCWs may be related to the greater change 
and instability they experience in their younger years [24]. 
Men tended to be more likely to be LTFU in our study, 
which is similar to the findings of Escurdero et al. [13].
The majority (207 out of 281) of HCWs in our study 
were doctors and students. Doctors and students are 
often involved in invasive medical procedures, which 
places them at risk of being exposed to infectious mate-
rial [7, 9, 11, 25]. Furthermore, students and doctors with 
less than a year’s experience, are prone to occupational 
exposure because of their inexperience [7, 9, 26]. We 
found that doctors are more likely to be LTFU than other 
HCW categories. This could be explained by the ease 
with which doctors can submit their own blood samples 
for HIV testing instead of attending the OHC. One study, 
[27] showed a large proportion of HCWs obtained HIV
testing outside of the facility where they worked, which
they suggested was due to concern surrounding the confi-
dentiality of HIV testing at the facility. Furthermore, doc-
tors may be making their own assessment of the severity
of the exposure and may deem it unnecessary to follow-
up [28]. In contrast to our findings of increased LTFU in
doctors, Gutierrez et  al. [6] showed cleaning personnel
were more likely to be LTFU. Two other studies found
type of HCW category did not influence attendance to
follow-up [12, 13].
Longer time from exposure to receiving PEP at the 
3-month visit was positively associated with LTFU. This
could be explained by HCWs who present after 24 h hav-
ing a perceived lower benefit from PEP. However, type of
exposure and source patient HIV status, which are asso-
ciated with risk of HIV acquisition, were not associated
with LTFU in our cohort.
Escudero et  al. [13] also found that type of exposure 
was not related to attendance to follow-up. Findings from 
studies that assessed the effect of the source patient’s HIV 
status on LTFU are contradictory, with one study report-
ing no effect, [6] while another found positive serological 
status was associated with improved follow up [13].
Table 2 Variables associated with loss to follow-up at 3 months
a  Reference category
Variables Unadjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age (per 10-year increase) 0.7 (0.5–0.9) 0.003 0.6 (0.5–0.9) 0.011
Sex
 Women a
 Men 1.4 (0.8–2.4) 0.190 1.4 (0.8–2.5) 0.262
Health care worker
 Allied health  professionala
 Doctor 2.9 (1.6–5.4) 0.001 2.7 (1.3–5.5) 0.006
 Student 2.0 (1.1–3.6) 0.022 1.2 (0.6–2.6) 0.584
Type of exposure
 Hollow-borea
 Mucocutaneous 1.6 (0.9–2.9) 0.095 1.1 (0.6–2.2) 0.707
 Solid sharp 1.3 (0.7–2.4) 0.377 1.0 (0.5–1.9) 0.948
Source patient HIV status
 Positive 0.9 (0.4–1.8) 0.742 0.5 (0.2–1.1) 0.074
 Unknowna
Antiretroviral
 Dual 1.4 (0.8–2.3) 0.250 1.5 (0.8–2.8) 0.228
 Triplea
Time from exposure to receiving PEP (h)
 <24a
>24 3.0 (1.0–9.2) 0.052 5.9 (1.3–26.9) 0.023
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There are a number of studies which reported that dual 
ART regimens are better tolerated than triple regimens 
[29, 30]. However, many of these studies include ART 
that are no longer used due to toxicity. Newer studies 
have shown that completion of PEP is based on the toler-
ability of ART and not on whether dual or triple therapy 
are used [31, 32]. This could explain why in our cohort 
there was no correlation between type of ART used and 
LTFU.
There were several limitations of our study. First, the 
retrospective cohort design is inherently prone to bias. 
However, the data was captured by OHC staff on a stand-
ard form and we had very little missing data. Second, 
although we found that time from exposure to receiving 
PEP was associated with LTFU, the 95% CIs were wide 
due to the small sample size of HCWs with delayed pres-
entation. Third, we did not explore associations between 
years of HCW experience and exposure as we did not 
have this data. Other researchers have reported an asso-
ciation between years of experience and the incidence of 
occupational exposures [7, 9, 25]. Finally, Groote Schuur 
Hospital is a tertiary facility with referrals from other 
hospitals that fall under the University of Cape Town, so 
our findings may not be generalizable to other settings 
such as district hospitals.
We have identified factors associated with LTFU, which 
could be used to target interventions to decrease LTFU. 
In one study, [13] contacting HCWs by telephone or 
mail improved attendance to follow-up from 33 to 54%. 
Schmid et  al. [33] suggested attendance to follow-up 
could be improved with fewer follow-up visits. The WHO 
has recently advised the final follow-up visit should be at 
3 months rather than 6 months [15]. Furthermore, it has 
been suggested that the last follow-up visit should be at 
6 weeks if laboratory 4th generation HIV ELISA tests are 
utilized, and 8 weeks if 4th generation rapid HIV tests are 
utilized [34]. Lastly van der Maaten et  al. [9] suggested 
increasing awareness of the availability of PEP through 
campaigns.












Age (per 10-year increase) 1.0 (0.7–1.3) 0.764 0.6 (0.5–0.9) 0.010
Sex
 Womena
 Men 1.8 (1.1–3.2) 0.027 1.8 (0.9–3.4) 0.082
Health care worker
 Allied health 
 professionala
 Doctor 2.1 (1.1–4.4) 0.034 2.1 (1.0–4.5) 0.049
 Student 1.1 (0.5–2.5) 0.750 1.3 (0.6–2.9) 0.532
Type of exposure
 Hollow-borea
 Mucocutaneous 1.0 (0.5–1.9) 0.988 1.2 (0.6–2.5) 0.659
 Solid sharp 1.1 (0.5–2.1) 0.857 1.1 (0.5–2.4) 0.728
Source patient HIV status
 Positive 1.0 (0.5–2.2) 0.952 0.7 (0.3–1.7) 0.489
 Unknowna
Antiretroviral
 Dual 1.2 (0.6–2.3) 0.544 0.7 (0.4–1.4) 0.333
 Triplea
Time from exposure to receiving PEP (h)
 <24a





















Allied Health Professionals Doctors Student
Fig. 2 Percentage loss to follow-up (LTFU) by number of visits of various health care worker categories (visits were scheduled at 6 weeks, 3 months, 
and 6 months). Error bars are shown
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Conclusion
We have identified factors associated with LTFU of 
HCWs after occupational HIV exposure. Future research 
should identify measures to improve attendance to fol-
low-up, which could be targeted at doctors, younger 
HCWs, and HCWs with delayed presentation.
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Your recent letter to the hospital refers. 
You are hereby granted permission to proceed with your research and is valid until 30th May 2017 
Please note the following: 
a) Your research may not interfere with normal patient care. 
b) Hospital staff may not be asked to assist with the research. 
c) No additional costs to the hospital should be incurred i.e. Lab, consumables or stationary 
may be used. 
d) No patient folders may be removed from the premises or be inaccessible.  
e) Please introduce yourself to the person in charge of an area before commencing. 
f) Please discuss the study with the HOD before commencing. 
g) Please provide the research assistant/field worker with a copy of this letter as verification of 
approval. 
h) Confidentiality must be maintained at all times. 
i) Should you require additional research time beyond the stipulated expiry date, please 
apply for an extension. 
j) Once research is complete, please submit a copy of the publication or report. 
 





DR BERNADETTE EICK 
CHIEF OPERATIONAL OFFICER 
Date: 20 May 2016 
BE/vms 
C.C. Mr L. Naidoo, Professor E. Weimann 
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